piracetam has been researched along with Adolescent Myoclonic Epilepsy in 22 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levetiracetam was well tolerated and effective as add-on treatment in partial and generalised seizures." | 5.32 | [Levetiracetam in the treatment of epilepsy]. ( Brodtkorb, E; Johannessen, SI; Lossius, R; Mariero Klees, T; Nakken, KO, 2003) |
| "Lennox-Gastaut syndrome is an epileptic encephalopathy characterized by multiple seizure types, mental retardation, and a slow spike-and-wave pattern on electroencephalography." | 5.32 | Levetiracetam in the treatment of Lennox-Gastaut syndrome. ( De Los Reyes, EC; Hale, SE; Sharp, GB; Williams, JP, 2004) |
| " Oral treatment with levetiracetam resolved his seizures." | 3.80 | Generalised electrographic seizures presenting as perioral myoclonia. ( Dearborn, JL; Kaplan, PW, 2014) |
| "Patients with juvenile myoclonic epilepsy (JME) may be resistant or show adverse effects to valproate." | 2.72 | Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. ( Boero, G; Gambardella, A; Giallonardo, AT; La Neve, A; Michelucci, R; Specchio, LM; Specchio, N, 2006) |
| "Levetiracetam was well tolerated; no patient reported side-effects." | 2.71 | Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. ( Di Bonaventura, C; Egeo, G; Fattouch, J; Giallonardo, AT; Manfredi, M; Mari, F; Prencipe, M; Vaudano, AE, 2005) |
| "Myoclonic jerks are frequently the debut symptom, while tonic-clonic seizures appear later on." | 2.48 | [Juvenile myoclonic epilepsy]. ( Markhus, R; Nakken, KO; Selmer, KK; Syvertsen, MR, 2012) |
| "Juvenile myoclonic epilepsy is a common idiopathic generalized epileptic syndrome that includes generalized myoclonic seizures and commonly generalized tonic-clonic and generalized absence seizures." | 2.45 | The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? ( Abou-Khalil, B; Montouris, G, 2009) |
| "Drug treatment of juvenile myoclonic epilepsy (JME) is mainly based on clinical experience and prospective and retrospective studies, with little evidence from randomized clinical trials." | 2.44 | Treatment of juvenile myoclonic epilepsy. ( Auvin, S, 2008) |
| "West syndrome is an age-dependent epilepsy with onset peak in the first year of life whose aetiology may be symptomatic or cryptogenic." | 1.39 | West syndrome followed by juvenile myoclonic epilepsy: a coincidental occurrence? ( Fontana, A; Giordano, G; Mangano, GR; Mangano, S; Nardello, R; Spitaleri, C; Tripi, G, 2013) |
| "When lamotrigine was restarted 2 weeks later she developed similar but more severe symptoms which resolved on stopping lamotrigine." | 1.35 | Anticonvulsant hypersensitivity syndrome presenting as aseptic meningitis. ( Bazaz, R; Lily, O; Maniyar, F; Rooney, C, 2009) |
| "We have treated a patient with juvenile myoclonic epilepsy who had frequent and inconvenient morning myoclonus with 3,200 mg of piracetam daily." | 1.33 | Antimyoclonic efficacy of piracetam in idiopathic generalized epilepsy. ( Andermann, E; Andermann, F; Khani, YA, 2005) |
| "Levetiracetam was well tolerated and effective as add-on treatment in partial and generalised seizures." | 1.32 | [Levetiracetam in the treatment of epilepsy]. ( Brodtkorb, E; Johannessen, SI; Lossius, R; Mariero Klees, T; Nakken, KO, 2003) |
| "Lennox-Gastaut syndrome is an epileptic encephalopathy characterized by multiple seizure types, mental retardation, and a slow spike-and-wave pattern on electroencephalography." | 1.32 | Levetiracetam in the treatment of Lennox-Gastaut syndrome. ( De Los Reyes, EC; Hale, SE; Sharp, GB; Williams, JP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (72.73) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mangano, S | 1 |
| Nardello, R | 1 |
| Tripi, G | 1 |
| Giordano, G | 1 |
| Spitaleri, C | 1 |
| Mangano, GR | 1 |
| Fontana, A | 1 |
| Dearborn, JL | 1 |
| Kaplan, PW | 1 |
| Chowdhury, A | 1 |
| Brodie, MJ | 1 |
| Auvin, S | 1 |
| Belcastro, V | 1 |
| Costa, C | 1 |
| Galletti, F | 1 |
| Rossi, A | 1 |
| Tambasco, N | 1 |
| Striano, P | 1 |
| Rosenfeld, WE | 1 |
| Benbadis, S | 1 |
| Edrich, P | 1 |
| Tassinari, CA | 1 |
| Hirsch, E | 1 |
| Maniyar, F | 1 |
| Rooney, C | 1 |
| Lily, O | 1 |
| Bazaz, R | 1 |
| Montouris, G | 1 |
| Abou-Khalil, B | 2 |
| Khan, S | 1 |
| Syvertsen, MR | 1 |
| Markhus, R | 1 |
| Selmer, KK | 1 |
| Nakken, KO | 3 |
| Karlov, VA | 1 |
| Freĭdkova, NV | 1 |
| Rusanova, LV | 1 |
| Mariero Klees, T | 1 |
| Brodtkorb, E | 2 |
| Lossius, R | 2 |
| Johannessen, SI | 2 |
| De Los Reyes, EC | 1 |
| Sharp, GB | 1 |
| Williams, JP | 1 |
| Hale, SE | 1 |
| Klees, TM | 1 |
| Khani, YA | 1 |
| Andermann, F | 1 |
| Andermann, E | 1 |
| Di Bonaventura, C | 2 |
| Fattouch, J | 2 |
| Mari, F | 1 |
| Egeo, G | 1 |
| Vaudano, AE | 1 |
| Prencipe, M | 1 |
| Manfredi, M | 1 |
| Giallonardo, AT | 3 |
| Specchio, LM | 2 |
| Gambardella, A | 2 |
| Michelucci, R | 2 |
| Specchio, N | 2 |
| Boero, G | 2 |
| La Neve, A | 2 |
| Plattner, B | 1 |
| Pahs, G | 1 |
| Kindler, J | 1 |
| Williams, RP | 1 |
| Hall, RE | 1 |
| Mayer, H | 1 |
| Steiner, H | 1 |
| Feucht, M | 1 |
| Sharpe, DV | 1 |
| Patel, AD | 1 |
| Fenichel, GM | 1 |
| Verrotti, A | 1 |
| Cerminara, C | 1 |
| Coppola, G | 1 |
| Franzoni, E | 1 |
| Parisi, P | 1 |
| Iannetti, P | 1 |
| Aloisi, P | 1 |
| Tozzi, E | 1 |
| Cusmai, R | 1 |
| Vigevano, F | 2 |
| Chiarelli, F | 1 |
| Curatolo, P | 1 |
| de Palo, A | 1 |
| Ladogana, M | 1 |
| Lamberti, P | 1 |
| Schauer, R | 1 |
| Singer, M | 1 |
| Saltuari, L | 1 |
| Kofler, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam (LEV) (Oral Tablets of 500 mg b.i.d.) at a Dose of 3000 mg/Day as Adjunctive Treatment in Adolescents (≥ 12 Years) and Adults (≤ 65 Year[NCT00150774] | Phase 3 | 116 participants | Interventional | 2001-11-30 | Completed | ||
| A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With 3000 mg/Day (Pediatric Target Dose of 60 mg/kg/Day) Oral Levetiracetam (LEV) (166, 250, and 500mg Tablets), in Adult and Ped[NCT00160550] | Phase 3 | 154 participants | Interventional | 2001-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for piracetam and Adolescent Myoclonic Epilepsy
| Article | Year |
|---|---|
Treatment of juvenile myoclonic epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Lamotrigine; Le | 2008 |
The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?
Topics: Anticonvulsants; Congenital Abnormalities; Delayed-Action Preparations; Drug Design; Epilepsy, Gener | 2009 |
[Juvenile myoclonic epilepsy].
Topics: Adolescent; Anticonvulsants; Diagnosis, Differential; Electroencephalography; Female; Humans; Lamotr | 2012 |
5 trials available for piracetam and Adolescent Myoclonic Epilepsy
| Article | Year |
|---|---|
Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blin | 2009 |
Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blin | 2009 |
Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blin | 2009 |
Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blin | 2009 |
Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes.
Topics: Anticonvulsants; Electroencephalography; Epilepsy, Absence; Female; Humans; Levetiracetam; Male; Myo | 2005 |
Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; Electroencephalography; Female | 2006 |
Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents.
Topics: Adolescent; Anticonvulsants; Child; Female; Follow-Up Studies; Humans; Levetiracetam; Male; Myocloni | 2008 |
Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Dose-Response Relationship, Drug; Drug Resistance; | 2008 |
14 other studies available for piracetam and Adolescent Myoclonic Epilepsy
| Article | Year |
|---|---|
West syndrome followed by juvenile myoclonic epilepsy: a coincidental occurrence?
Topics: Adolescent; Brain; Disease Progression; Humans; Infant; Levetiracetam; Magnetic Resonance Imaging; M | 2013 |
Generalised electrographic seizures presenting as perioral myoclonia.
Topics: Adult; Diagnosis, Differential; Electroencephalography; Humans; Levetiracetam; Male; Myoclonic Epile | 2014 |
Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate.
Topics: Adolescent; Adult; Anticonvulsants; Child; Comorbidity; Drug Resistant Epilepsy; Female; Follow-Up S | 2016 |
Rapid effect of levetiracetam in a case of juvenile myoclonic epilepsy.
Topics: Adult; Anticonvulsants; Electroencephalography; Epilepsy, Tonic-Clonic; Female; Humans; Levetiraceta | 2009 |
Anticonvulsant hypersensitivity syndrome presenting as aseptic meningitis.
Topics: Anti-Bacterial Agents; Anticonvulsants; Drug Administration Schedule; Drug-Related Side Effects and | 2009 |
Juvenile myoclonic epilepsy.
Topics: Anticonvulsants; Electroencephalography; Family Health; Humans; Levetiracetam; Mutation; Myoclonic E | 2010 |
[Complex therapy of idiopathic forms of epilepsy with small doses of valproates and levetiracetam].
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy, Absence; | 2012 |
[Levetiracetam in the treatment of epilepsy].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Interactions; Epilepsy; Female; Follow-Up Studies; Hu | 2003 |
Levetiracetam in the treatment of Lennox-Gastaut syndrome.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy, Generaliz | 2004 |
Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Drug Resistance; Drug Th | 2004 |
Antimyoclonic efficacy of piracetam in idiopathic generalized epilepsy.
Topics: Comorbidity; Epilepsy, Generalized; Female; Follow-Up Studies; Humans; Middle Aged; Myoclonic Epilep | 2005 |
Juvenile myoclonic epilepsy: a benign disorder? Personality traits and psychiatric symptoms.
Topics: Adolescent; Adult; Anticonvulsants; Child; Ethosuximide; Female; Fructose; Humans; Lamotrigine; Leve | 2007 |
Levetiracetam monotherapy in juvenile myoclonic epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Data Interpretation, Statistical; Electroencephalography; | 2008 |
Suppression of cortical myoclonus by levetiracetam.
Topics: Adolescent; Anticonvulsants; Cerebral Cortex; Dominance, Cerebral; Drug Therapy, Combination; Epilep | 2002 |